NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AIRNA

AIRNA

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://airna.com/

Last Round

Series B

Apr 1, 2025

Total Funding Raised

$305M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

AIRNA is a biotechnology company that develops RNA-editing therapeutics to treat rare and common diseases by leveraging its proprietary RESTORE+™ platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA editingtherapeutic pipelineAlpha-1 Antitrypsin DeficiencyAATDgenetic medicineoligonucleotide therapeuticsclinical-stage biotechgene editingRNA therapeuticsbiotech startupdrug developmentcardiometabolic diseasetherapeutic platformbiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AIRNA Comps

Public and private peers based on sector, stage, and business model.

AIRNA comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AIRNA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 1, 2025
Series A ExtensionJul 31, 2024
Series ASep 19, 2023

Key People

Founding team and executive leadership

Allison Dorval

CFO

Executive Team

AIRNA Investors

Notable investors and investment history

AIRNA investors
InvestorRounds
LifeLink VenturesSeries B
Codon CapitalSeries A
ForbionSeries B, Series A, Series A Extension
ARCH Venture PartnersSeries B, Series A Extension, Series A
+ND CapitalSeries B, Series A, Series A Extension
ARCH Venture PartnersSeries B, Series A Extension, Series A
Alexandria Venture InvestmentsSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 22, 2026

    Developing new medicines for rare and common diseases, starting with AATD.

  • Oct 1, 2025

    Niru Subramanian appointed as the new COO.

AIRNA Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AIRNA Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AIRNA's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range84
Year Founded2021
Last FundingApr 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.